According to a recent LinkedIn post from Bioxodes SA, final data from its Phase 2a BIRCH trial of BIOX-101 in acute intracerebral hemorrhage have been selected for a Late-Breaking Science oral presentation at the 18th World Stroke Congress in Seoul. The post indicates that the data show statistically significant improvements across multiple secondary endpoints, with follow-up to Day 360.
The company’s LinkedIn post highlights comments attributed to Dr. Dimitri Hemelsoet of Ghent University Hospital, suggesting BIOX-101 was safe, achieved rapid target engagement, and showed encouraging signals of reduced secondary injury and improved recovery. These findings are described as supporting progression to a later-phase trial.
The post notes that no treatment has yet been approved for intracerebral hemorrhage, positioning BIOX-101 as a first-in-class candidate in a high-unmet-need stroke indication. This context may underscore the potential strategic value of the asset if efficacy and safety are confirmed in larger studies.
As shared in the post, Bioxodes is preparing BIRCH 2, a planned Phase 2b trial of BIOX-101 in approximately 200 ICH patients, and is in discussions with potential partners and investors to finance the study. The need for external funding and partnering could influence the company’s capital structure and timelines for advancing the program.
The LinkedIn post also mentions that Bioxodes intends to host a key opinion leader event and live investor webcast following the congress presentation, with details to follow separately. For investors, these events may provide additional clinical detail, clarity on trial design for BIRCH 2, and insight into potential partnering or financing arrangements.